LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
| العنوان: | LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial |
|---|---|
| المؤلفون: | Petrie, JR, Marso, SP, Bain, SC, Franek, E, Jacob, S, Masmiquel, L, Leiter, LA, Haluzik, M, Satman, I, Omar, M, Shestakova, M, Van Gaal, L, Mann, JF, Baeres, FM, Zinman, B, Poulter, NR, LEADER investigators |
| المساهمون: | Imperial College Healthcare NHS Trust- BRC Funding, National Institute for Health Research, LEADER Investigators |
| المصدر: | Journal of hypertension Journal of Hypertension |
| بيانات النشر: | Lippincott Williams & Wilkins, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, estimated glomerular filtration rate, type 2 diabetes mellitus, Physiology, Blood Pressure, Type 2 diabetes, 030204 cardiovascular system & hematology, SGLT-2, law.invention, 0302 clinical medicine, Randomized controlled trial, Risk Factors, cardiovascular disease, law, eGFR, LEADER investigators, 030212 general & internal medicine, sodium–glucose linked transporter-2, LEADER, Middle Aged, CVD, Hypertension, targets, Female, Cardiology and Cardiovascular Medicine, medicine.drug, medicine.medical_specialty, liraglutide effect and action in diabetes, evaluation of cardiovascular outcome results, Randomization, 1102 Cardiovascular Medicine And Haematology, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, Double-Blind Method, ORIGINAL PAPERS: Diabetes mellitus, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Intensive care medicine, Antihypertensive Agents, Aged, Liraglutide, business.industry, Type 2 Diabetes Mellitus, 1103 Clinical Sciences, medicine.disease, Clinical trial, Blood pressure, Diabetes Mellitus, Type 2, glucagon-like peptide-1, Cardiovascular System & Hematology, North America, Human medicine, GLP-1, business, regional differences |
| الوصف: | Objective: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial.\ud \ud Methods: We analyzed baseline data from LEADER (NCT01179048), an ongoing phase 3B, randomized, double-blind, placebo-controlled cardiovascular outcomes trial examining the cardiovascular safety of the glucagon-like peptide-1 receptor agonist liraglutide in 9340 people with T2DM from 32 countries [age (all mean +/- SD) 64 +/- 7.2 years, BMI 32.5 +/- 6.3 kg/m2, duration of diabetes 12.7 +/- 8.0 years], all of whom were at high risk for cardiovascular disease (CVD).\ud \ud Results: A total of 81% (n = 7592) of participants had prior CVD and 90% (n = 8408) had a prior history of hypertension. Despite prescription of multiple antihypertensive agents at baseline, only 51% were treated to a target BP of less than 140/85 mmHg and only 26% to the recommended baseline BP target of less than 130/80 mmHg. In univariate analyses, those with prior CVD were prescribed more agents (P < 0.001) and had lower BP than those without (137 +/- 18.8/78 +/- 10.6 mmHg versus 140 +/- 17.7/80 +/- 9.9 mmHg; P < 0.001). In logistic regression analyses, residency in North America (64% treated to |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0263-6352 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bde80e35bc7f47df055c0d2b64ac39Test https://eprints.gla.ac.uk/116246/1/116246.pdfTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....76bde80e35bc7f47df055c0d2b64ac39 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 02636352 |
|---|